Phase 3 N=3,411 CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
COVID 19
Primary: Number of Participants With Symptomatic COVID-19 at 60 Days — 24; 19 Participants — p=0.52
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=245 Transmission of Coronavirus Disease 2019 (COVID19) in Crowded Environments
Covid19 · Sars-CoV-2 Infection
Primary: SARS-CoV-2 Infection — 4; 2 Participants
N/A N=112 Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
COVID-19
Primary: Evaluation of Acceptability of Intervention as Measured by Acceptability Questionnaire — 4.47 score on a scale
N/A N=4,142 COVID-19: Human Epidemiology and Response to SARS-CoV-2
Coronavirus Disease 2019 (COVID-19) · SARS-CoV-2
Primary: Number of Index Participants and Their Household Contacts With SARS-CoV-2 RNA Detection in Nasal Samples Over the Study/Surveillance Period — 98.9; 99.2; 99.1; 98.0…
N/A N=2,598 HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV
HIV-1-infection · COVID-19
Primary: Number of Composite Primary End Point (Critical Care Admission, Palliative Discharge When Discharged From Hospital, or Mortality Within the 6 Weeks After Diagnosis of…
Phase 4 N=44 Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol)
Diarrhea · COVID-19
Primary: Measure of Daily Stool Frequency for Patients With COVID Treated With Bismuth — 3 bowel movements
Phase 1 N=18 This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)
SARS-CoV-2 Infection
Primary: Number of Patients With TEAEs — 3; 4; 3; 1 Participants
N/A N=15 Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)
Coronavirus
Primary: Deterioration Resulting in Healthcare Review — 10 alerts generated
N/A N=7,444 Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19)
Healthy
Primary: PTSD Symptom Severity — 16.36; 17.10; 15.56; 15.78 score on a scale — p=.77
N/A N=69 Detection of SARS-CoV-2 RNA in Coughed Droplets From Patients With COVID-19
Covid19
Primary: Sensitivity of Detecting SARS-CoV-2 RNA — 31; 0 Participants
N/A N=820 The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign
Covid19
Primary: Facebook Movement Metric — -6.082; -5.320; -2.603; -1.823 Percent change relative to Feb 2020
N/A N=3,632 Epidemiological Study of the COVID-2019 in Participating Organizations.
Covid19
Primary: The Incidence of COVID-2019 Cases. — 259.95 COVID-2019 cases per 1000 person
Phase 2 N=25 Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
Covid19 · Pneumonia, Viral
Primary: Count of White Blood Cells (WBC) After 99mTc-pertechnetate Aerosol Inhalation for Adverse Events Monitoring as Evaluation Safety of This Procedure in Patients With…
Phase 2 N=47 Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19)
COVID-19
Primary: Number of Participants Requiring Mechanical Ventilation or Dying — 3; 3 Participants
N/A N=118 Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
Covid19
Primary: Number of Participants With National Early Warning Score (NEWS) Change From 3 to 0 — 44; 29 Participants
Phase 2 N=124 Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19)
Primary: The Percent of Participants With Tracheal Intubation or Death Prior to Tracheal Intubation — 26.2; 22.2 percentage of participants
N/A N=270 The Impact of the COVID-19 (SARS-CoV-2 Disease) on Psychopathology
Psychosis;Schizophrenic · Personality Disorders · Mood Disorders
Primary: Brief Psychiatric Rating Scale (BPRS) — 29.30; 32.80; 30.25 score on a scale
N/A N=172 Addressing COVID-19 Mental Health Problems Among US Veterans
Brief Video-based Intervention · Vignette Based Intervention · Non Intervention Control Arm
Primary: Help Seeking Intention — 7.4; 7.9; 7.3; 8.2 units on a scale — p=0.031
Phase 3 N=49 Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
COVID-19
Primary: Number of Subjects Experiencing TEAEs — 16; 12; 9; 2 Participants
N/A N=1,102 Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic
COVID-19
Primary: Number and Severity of Confirmed COVID-19 Infections Among Cancer Centre Staff and Patients at 12 Months — 55; 36 Participants
Phase 1 N=150 N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)
Coronavirus · Covid19
Primary: Number of Participants Intubated During Hospitalization — 8; 25 Participants — p=0.297
N/A N=479 COVID-19 Observational Research Collaboratory
COVID-19 · SARS-CoV-2 Infection
Primary: Instrumental Activities of Daily Living and Activities of Daily Living (I/ADL) Score — 3.40; 3.05; 3.50; 3.40 I/ADL Score — p=0.77
Phase 2 N=46 Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
CoronaVirus Induced Disease-2019 (COVID-19)
Primary: Percentage of Participants Alive and Without Respiratory Failure Through Day 28 — 86.4; 79.2 percentage of participants — p==0.599
Phase 2 N=180 Convalescent Plasma to Stem Coronavirus (CSSC-001)
Coronavirus · Convalescence
Primary: Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection — 12; 13 Participants — p=0.42
Phase 2 N=30 Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.
Covid19 · SARS-CoV-2 PNEUMONIA · COVID-19
Primary: Number of Participants With Non-serious and Serious Adverse Events During Trial — 0; 0; 0; 0 Participants
N/A N=36 COVID-19 SARS-CoV-2 Screening Protocol
Covid19
Primary: Participants Enrolled — 36 Participants
Phase 2 N=228 CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)
Corona Virus Infection
Primary: Percentage of Participants With WHO Clinical Progression Scale > 5 at Day 4 -- Severe COVID Population (WHO Clinical Progression Scale =5 at Baseline) — 19; 28…
Phase 2 N=41 Nebulised Dornase Alfa for Treatment of COVID-19 (Coronavirus Disease 2019)
COVID-19 (Coronavirus Disease 2019) · Hypoxia
Primary: Measuring the Change in Inflammation — 23.23; 34.82 mg/L — p=0.01
Phase 3 N=814 Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation
COVID
Primary: Cohort 1, Phase 2: Percentage of Participants Alive and Free of Mechanical Ventilation at Day 29 — 85.7; 87.5; 74.4 percentage of participants — p=0.2598
N/A N=2,778 You and Me COVID Free
COVID-19
Primary: Main Reason for Testing for COVID-19 — 1632; 493; 238; 343 Participants